4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Chardan Capital

Posted by Geri Gentry on Jul 31st, 2026

Chardan Capital upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.88.

Check Out Our Latest Research Report on FDMT

4D Molecular Therapeutics Trading Up 4.8%

FDMT stock opened at $10.07 on Tuesday. The stock has a market capitalization of $526.42 million, a price-to-earnings ratio of -3.92 and a beta of 2.70. The firm’s 50-day moving average price is $10.55 and its two-hundred day moving average price is $9.64. 4D Molecular Therapeutics has a 12-month low of $4.30 and a 12-month high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities analysts predict that 4D Molecular Therapeutics will post -3.8 EPS for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 184,811 shares of company stock valued at $2,075,906. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Exome Asset Management LLC purchased a new stake in 4D Molecular Therapeutics in the first quarter worth $1,216,000. Simplify Asset Management Inc. bought a new position in 4D Molecular Therapeutics in the first quarter worth $656,000. Evergreen Quality Fund GP Ltd. purchased a new position in 4D Molecular Therapeutics during the fourth quarter valued at $7,136,000. Baker BROS. Advisors LP purchased a new position in 4D Molecular Therapeutics during the fourth quarter valued at $3,568,000. Finally, Armistice Capital LLC boosted its holdings in shares of 4D Molecular Therapeutics by 76.6% during the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after buying an additional 840,000 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.